Clinical Trial Update: Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic interaction study assessing the effect of repeat doses of rifampin on mirabegron (YM178) in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)
• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Pharmacokinetics of YM178 | Phase 1 | Status: COMPLETED